Head and Neck Cancer Trial, Recruiting NCT06103669 Sponsor: University of California, Davis Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT06103669
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with one of the following cancer types, confirmed by lab testing: breast cancer, gynecological cancer, head and neck cancer, sarcoma, or another solid tumor cancer specified by the study.
  • You are willing and able to sign a consent form agreeing to take part in the study.
  • You are willing to follow all study procedures and are available for the full length of the study.
  • You are 18 years old or older at the time of joining.
  • You are currently receiving systemic treatment (such as chemotherapy or other cancer medicines) and are able to continue that same treatment, with no more than a 30-day pause to allow for a targeted local treatment.
  • You have received at least one round of systemic treatment for cancer that has spread, and your most recent treatment has been working well enough for at least 3 months before any new or growing spots appeared — meaning most of your cancer has been stable and your doctor has not needed to change your treatment.
  • You have 5 or fewer spots of cancer that are new or getting larger.
  • All of your new or growing cancer spots can be safely treated with a focused local treatment, as decided by your specialist doctors (radiation oncologist and/or interventional radiologist).

Who may not be able to join:

  • You have other health conditions that would make it unsafe to receive a focused local treatment.
  • You have had side effects from previous treatments that would make it difficult or unsafe to receive a focused local treatment.
  • You have cancer spots that are growing inside the brain.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiao Zhao, MD, University of California, Davis

Phone: 916-382-6970

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 October 2023
Est. completion
1 December 2033

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with controlled disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov